The classification, genetic diagnosis and modelling of monogenic autoinflammatory disorders

Fiona Moghaddas1,2 and Seth L. Masters1,2

1Inflammation Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia; 2Department of Medical Biology, The University of Melbourne, Parkville, Australia

Correspondence: Fiona Moghaddas (moghaddas.f@wehi.edu.au)

Monogenic autoinflammatory disorders are an increasingly heterogeneous group of conditions characterised by innate immune dysregulation. Improved genetic sequencing in recent years has led not only to the discovery of a plethora of conditions considered to be ‘autoinflammatory’, but also the broadening of the clinical and immunological phenotypic spectra seen in these disorders. This review outlines the classification strategies that have been employed for monogenic autoinflammatory disorders to date, including the primary innate immune pathway or the dominant cytokine implicated in disease pathogenesis, and highlights some of the advantages of these models. Furthermore, the use of the term ‘autoinflammatory’ is discussed in relation to disorders that cross the innate and adaptive immune divide. The utilisation of next-generation sequencing (NGS) in this population is examined, as are potential in vivo and in vitro methods of modelling to determine pathogenicity of novel genetic findings. Finally, areas where our understanding can be improved are highlighted, such as phenotypic variability and genotype–phenotype correlations, with the aim of identifying areas of future research.

Introduction

The phrase ‘autoinflammatory disease’ was proposed as an alternative to ‘autoimmune disease’ by Mc Dermott et al. [1] in the paper identifying the genetic cause of Tumour Necrosis Factor (TNF) Receptor Associated Periodic Syndrome (TRAPS). This was considered a suitably representative term at the time, as individuals with inherited periodic fever syndromes had innate immune dysregulation but lacked high titres of autoantibodies and self-reactive T cells [1]. Familial Mediterranean Fever (FMF) was the only genetically defined periodic fever syndrome prior to this publication and the clinical and biochemical features appeared to be well defined [2,3].

Since this time, over 30 conditions have been added to the list of monogenic autoinflammatory disorders. The significant broadening of clinical features, pathway perturbations and genes involved bring into question the utility of the original definition of these disorders, and whether an alternative is required that better encapsulates the spectrum of immune dysregulation seen. Highlighting the complexity of this task, the list of conditions considered ‘autoinflammatory’ by the International Union of Immunological Societies (IUIS) is incongruent with the Infevers database, a registry of mutations associated with autoinflammatory disorders maintained by the International Society for Systemic Autoinflammatory Diseases (ISSAID) (Figure 1) [4,5].

Classification

The term inflammasomopathy was introduced in the first review of autoinflammatory disorders categorising conditions based on the pathway implicated in disease pathogenesis [6], including disorders affecting inflammasomes, the nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) pathway, the complement system, protein folding, ‘cytokine signalling’ and those resulting in or from macrophage...
Figure 1. Genes involved in monogenic autoinflammatory disorders
Genes involved in monogenic autoinflammatory disorders according to ISSAID as listed in the Infevers database, compared with the IUHIS.

The pathway model
The pathway model has the advantage of highlighting possible targets for treatment downstream of an abnormal protein, as with Janus kinase (JAK) inhibitors for individuals with stimulator of IFN genes (STING)-associated vasculopathy with onset in infancy (SAVI), as well as possible candidate genes for autoinflammatory disorders, such as that encoding a member of the linear ubiquitin assembly complex (LUBAC), SHARPIN. There are, however, limitations to this classification. A clear example is the case of mutations in TNFRSF1A causing TRAPS. While TNF receptor 1 (TNFRI) is a key receptor in the NF-κB pathway, the disease is not necessarily caused by increased signalling through this pathway alone [1,9-13]. A number of pathogenic mechanisms have been explored, such as defective shedding of TNFRI [1], retention of TNFRI in cytoplasmic aggregates with reduced surface expression [11], and abnormal apoptosis and signalling [12].

This classification also neglects the complex interaction between signalling pathways that exist. NF-κB translocation to the nucleus is important for the expression of pro-IL-1β and NOD-like receptor (NLR) pyrin domain containing 3 (NLRP3), and the consequence of NF-κB dysfunction on inflammasome activation cannot be discounted. Key players in the regulation of NF-κB are also implicated in the regulation of NLRP3, as seen with A20 and the possible role of inflammasome activation in the inflammatory manifestations of haploinsufficiency of A20 (HA20) [14]. Furthermore, although not yet shown in human cells, transforming growth factor (TGF)-β activated kinase-1 (TAK1) has been shown to regulate NLRP3, with spontaneous NLRP3 activation documented in TAK1-deficient murine macrophages [15]. The NF-κB and IFN pathways are also intimately linked, with a number of sensors leading to activation of both pathways. In the case of SAVI, literature to date suggests that the IFN pathway is dysregulated in this syndrome [16,17], but whether these two pathways are actually uncoupled in the case of an overactive STING in vivo is unclear. Breeding mutant STING mice to Irf3<sup>−/−</sup> mice did not rescue the inflammatory phenotype, raising questions, at least in the murine model, of the role of IFN regulatory transcription factor (IRF) 3 in the inflammation associated with SAVI [18]. Furthermore, the role of NF-κB as a member of the IFN-β enhanceosome [19], a multicomponent complex that optimises transcriptional activation of IFN-β, suggests that the pathways are closely connected.
The cytokine model

An alternative classification strategy is based on the primary cytokine dysregulated, either increased or decreased, in individuals with autoinflammatory disorders [20]. This is of potential therapeutic benefit as the primary cytokine driving disease can be therapeutically targeted. An example of this is the treatment of individuals with cryopyrin-associated periodic syndrome (CAPS). In the original manuscript linking Neonatal Onset Multisystem Inflammatory Disease (NOMID) to mutations in NLRP3, cell lysates from unstimulated monocytes of a case had high pro-IL-1β expression as determined by Western blot, and increased IL-1β mRNA in unstimulated peripheral blood mononuclear cells (PBMCs) when compared with healthy controls [21]. The empiric treatment of two cases with recombinant IL-1 receptor antagonist and the rapid resolution of symptoms within hours, and inflammatory markers within days, highlighted the role of IL-1β in the disease pathogenesis [22]. Having said this, the detection of IL-1β in serum of cases is difficult, with both cases and healthy controls having levels below the detection limit of currently available assays. Most publications looking at the IL-1β levels and response to treatment in individuals with CAPS culture PBMCs and measure cytokine release over a 24-h period. The spontaneous secretion of IL-1β by CAPS PBMCs decreases with the initiation of IL-1β-targeted therapy [23]. From this it is clear that even without elevated serum levels, a therapeutic response to IL-1β neutralising therapy suggests that this cytokine is important [23,24]. The response of individuals with colchicine-resistant FMF [25], mevalonate kinase deficiency (MKD) [26], and TRAPS [27] to the neutralising anti-IL-1β antibody canakinumab, suggests that IL-1β is a key cytokine in all of these disorders. Supporting this is evidence of increased expression of IL1B and IL1R1 as determined by microarray in individuals with TRAPS [28]. The gene expression profile of TRAPS moved towards the healthy control profile with canakinumab treatment [27]. More recently, the randomised, double-blind, placebo-controlled study of canakinumab in the above groups demonstrated efficacy in controlling and preventing disease flares [29]. An interesting addition to the literature was a retrospective analysis by Savic et al., of individuals with undifferentiated systemic autoinflammatory disorders who were treated with anakinra [30]. A total of 11 cases were identified over a 3-year period, and nine responded completely to treatment with anakinra within 4–6 weeks of commencement. Although individuals had undergone Sanger sequencing for NLRP3, MEFV, TNFRSF1A and NOD2 with no pathogenic mutations detected, the marked response to treatment suggests that genes in the IL-1β pathway could be further interrogated for variants that may be causing disease. Conversely, subjects could undergo a broader approach with whole exome sequencing (WES) or whole genome sequencing (WGS) and novel genes involved in the IL-1β pathway may be revealed.

Evaluation of the major cytokine/s involved in monogenic autoinflammatory disorders may point to distinctions between conditions within the same pathway. The gain of function mutations in inflammasome forming proteins that lead to disease can be presumed to cause an increase in IL-1β processing and release. Mutations in NLRC4 that result in an autoinflammatory phenotype are associated with markedly increased serum free IL-18 levels in cases when compared with healthy controls and individuals with CAPS [31,32,33].

There are also conditions that may involve pathways distinct from those used to categorise autoinflammatory disorders in the literature. Through the study of autosomal recessive generalised pustular psoriasis (GPP) in a number of multiplex families, Marrakchi et al. [34] identified homozygous missense mutations in IL36RN, which encodes the IL-36 receptor antagonist (IL-36Ra), causing deficiency in IL-36Ra (DIRTIRA). IL-36 is a member of the IL-1 family of cytokines and, like IL-1β, acts via its receptor IL-36R and, in concert with IL-1 receptor accessory protein (IL1RaCP), signals to NF-κB through myeloid differentiation primary response 88 (MyD88). The binding of IL-36Ra to IL-36R prevents the association of IL1RaCP and downstream signalling. While there have been four case reports of the successful treatment of DITRA with anakinra therapy [35–38], therapeutic benefit has also resulted from TNF inhibition [39–41], IL-7 inhibition with secukinumab [42] and IL-12/IL-23 inhibition with ustekinumab [43–45]. This suggests that these agents may be targeting cytokines that are downstream of IL-36 [38]. The possibility of developing a therapeutic agent that is specific for IL-36 has been explored. Mbow et al. characterised a mouse anti-human antibody (MAB92) with high affinity to the IL-36 receptor that blocks signalling through this pathway [46]. Although highly specific for human IL-36R, the authors created MAB04, which cross-reacts with murine IL-36R for in vivo studies. Importantly, MAB04 inhibited imiquimod- and IL-36-induced skin inflammation in mice.

Deficiency in regulatory cytokines have also been described, and the clinical course of these individuals has been tumultuous. Homozygous mutations in IL10, IL10RA or IL10RB, leading to deficiencies in IL-10, IL-10RA or IL-10RB respectively, have been reported to cause monogenic early onset inflammatory bowel disease (EOIBD) [47,48]. IL-10 has regulatory effects on the inflammatory response which are mediated through signal transducer and activator of transcription (STAT) 3, with IL-10-deficient mice developing chronic enterocolitis [49–51]. PBMCs from cases with loss of function of these proteins had higher proinflammatory cytokine responses to lipopolysaccharide (LPS) stimulation, including IL-6, TNF and IL-1β, when compared with healthy controls [48]. Although multiple agents have
been trialled in these cases including corticosteroids, azathioprine, methotrexate, cyclosporine A and anti-TNF therapy, only mild clinical benefit has resulted [52]. A number of cases have undergone allogenic haemopoetic stem cell transplantation (HSCT) with marked improvement in their inflammatory bowel disease [52,53]. While recombinant human IL-10 replacement (rhIL-10) in individuals with IL-10 deficiency would seem to be a therapeutic option, there have been issues with the response to and side effects from rhuIL-10 in trials of individuals with Crohn’s disease [54]. Furthermore, this option would not be effective in individuals with mutations in IL10RA or IL10RB. At this point in time, HSCT is the only curative option.

A number of other conditions are presumed to result from dysregulation of a particular pathway because of their cytokine profile, but little is known about the steps that lead to this alteration. Proteasome-associated autoimmune inflammatory syndrome (PRAAS) is an autosomal recessive autoimmune inflammatory disorder that encompasses conditions previously considered distinct entities: Nakajo-Nishimura syndrome (NKJO), joint contractures, muscular atrophy, microcytic anaemia, and panniculitis-induced lipodystrophy syndrome (JMP), as well as chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature syndrome (CANDLE). Three publications identified mutations in PSMB8, the β5i catalytic component of the immunoproteasome, as the cause of disease [55-57]. Individuals with homozygous loss of function mutations in PSMB8 experienced spontaneous febrile episodes with features of muscle weakness, lipodystrophy as well as neutrophilic and lymphocytic infiltrative skin nodules and evidence of cerebral calcification [55-57]. Homozygous mutations were associated with poor proteasome assembly as well as reduced chymotrypsin-like activity and accumulation of ubiquitinated proteins in either Epstein–Barr virus (EBV)-transformed B cells or immortalised lymphoblastoid cell lines from cases [55-57]. In these early papers, increased serum IL-6 was noted in all cases, but the role of IFN was only identified later [58]. Liu et al. noted an almost 80-fold increase in IFN-γ-inducible protein 10 (IP-10) in cases compared with healthy controls and individuals with CAPS, prompting whole blood microarray analysis to determine the gene signature of these cases. The IFN pathway was the most differentially regulated pathway in individuals with PRAAS, further supported by stronger STAT1 phosphorylation in response to IFN-γ stimulation of monocytes when compared with healthy controls. These authors also highlighted cases with the clinical phenotype of PRAAS without PSMB8 mutations, later explored by Goldbach-Mansky et al. [59]. Digenic mutations involving PSMA3 or PSMB4 and PSMB8 or PSMB9, encoding constitutive proteasome subunits α7 and β7 or inducible subunits β5i and β11 respectively, were found in cases with the clinical diagnosis of PRAAS. One individual harboured a compound heterozygous mutation in PSMB4, and another a heterozygous mutation in POMP, encoding proteasome maturation protein. Similar to earlier reports, the mutant subunits were not efficiently assembled into the proteasome, resulting in reduced proteolytic activity. When compared with cases with homozygous PSMB8 mutations, the chymotryptic proteolytic activity was less impaired, but deficiencies were noted in tryptic and caspase proteolytic activity. Similar to homozygous PSMB8 mutations, there was inefficient clearing of ubiquitinated proteins and the presence of a type I IFN gene signature. Both siRNA models and proteasome inhibitors were used to recapitulate the IFN signature in PBMCs and fibroblasts. However, the mechanism/s by which proteasomal dysfunction leads to this response remains elusive. Classifying PRAAS by its IFN gene signature guides potential treatment considerations and also opens avenues for researchers to determine the role of the immunoproteasome in the IFN pathway.

Clarifying the dominant cytokine or pathway implicated in disease may lead to the development of targeted therapeutic strategies for autoimmune inflammatory conditions, as reviewed in recent publications [60,61]. Recent work has looked at individuals with interferonopathies treated with JAK1/2 inhibitor baricitinib. Initial work was performed by Goldbach-Mansky et al. to determine a dosing regimen for paediatric cases with interferonopathies [62]. This work was then extended with treatment of a number of individuals with interferonopathies including PRAAS and SAV1 and longitudinal assessment of response and adverse reactions [63]. Most patients were able to reduce their prednisolone requirements and five out of ten PRAAS cases achieved remission. Adverse events included upper respiratory infections, gastroenteritis and BK viremia. Given that only 18 patients were recruited over a span of 6 years, more work is needed to establish the clinical efficacy and adverse reaction profile in this selected population. The availability of this drug on compassionate grounds through NCT01724580 suggests that more information will become available in the future with ongoing recruitment and follow-up of these cases.

Similarly, elucidating elevated serum free IL-18 levels in an individual with autoimmune inflammation with infantile enterocolitis, an NLRRC4-associated autoimmune inflammatory disease, lead to the successful therapeutic trial of a recombinant IL-18 binding protein (rhlL-18) [64]. Following from this, there is a Phase 3 randomised, double-blind, placebo-controlled trial of rhIL-18 in NLRRC4-associated autoimmune inflammatory diseases (NCT03113760) as well as an open-label extension (NCT03512314) underway. This not only highlights the importance of identifying driver or dominant cytokines for possible therapeutic manipulation, but also the potential differences between inflammasome effector and regulatory mechanisms as well as possible epigenetic factors, that results in one cytokine dominating over another.
Autoinflammation, autoimmunity and immune deficiency

The boundaries of what is classified as an autoinflammatory disorder are also being blurred. The strict definition of innate immune dysregulation without self-reactive T cells or high titres of autoantibodies is increasingly in question, especially when one considers interferonopathies such as Aicardi–Goutières syndrome (AGS). AGS was originally described in the 1980s as a disorder of the central nervous system (CNS) associated with lymphocytosis in cerebrospinal fluid analysis and bilateral basal ganglia calcifications [65]. The genetic causes of AGS are numerous, and all involve the processing of nucleic acid, either self or foreign, in the cytoplasm. Loss of function mutations in genes encoding deoxyribonuclease three prime repair exonuclease 1 (TREX1) [66], deoxyribonucleotide triphosphohydrolase SAM and HD domain containing protein 1 (SAMHD1) [67], ribonuclease components ribonuclease H2 (RNASEH2) A (RNASEH2A), RNASEH2B or RNASEH2C [68], or adenosine deaminase acting on RNA 1 (ADAR1) [69] have been identified in individuals with AGS. The link between AGS and autoimmunity was initially made when Aicardi and Goutières speculated that the phenotype of two individuals with infantile systemic lupus erythematosus overlapped AGS considerably. They hypothesised that the two may be either the same condition or linked by an increase in IFN-α [70]. The phenotypic link has subsequently been highlighted by a number of groups [71,72], although the number of subjects in a large cohort of 374 mutations confirmed that AGS with clinically diagnosed lupus was low [73]. An abnormal serum autoantibody profile was seen in a minority of individuals with AGS in one cohort study [74], however another detected persistent antinuclear antibodies (ANA) or autoantibodies against extractable nuclear antigens (ENA), dsDNA and cardiolipin in the majority of their cases with mutation confirmed AGS [72]. Subsequent work using multiplex autoantibody microarrays identified unique autoantibodies in cases with AGS [75]. Whether this condition, and indeed other interferonopathies, should be considered autoimmune or autoinflammatory is a matter of debate. AGS highlights that this distinction is not always clear.

Indeed, the spectrum of immune dysregulation and overlap between autoimmunity, autoinflammation and immune deficiencies has been seen in a number of recently described conditions. Homozygous loss of function mutations in HOI1 or HOIP have been described in cases with evidence of systemic inflammation, susceptibility to pyogenic infections, and amylopectinosis [76,77]. The original description by Boisson et al. highlighted the importance of haem-oxidised IRP2 ubiquitin ligase 1 (HOI1) in maintaining the stability of the LUBAC, involved in the ubiquitination of components in the NF-κB pathway, as well as promoting the association of inhibitor of NF-κB kinase subunit γ (IKKγ) with TNF or IL-1 receptor signalling complexes [76]. The authors noted cell-type specific defects associated with HOI1 deficiency. Fibroblasts and EBV-immortalised B cells from subjects displayed impaired canonical NF-κB pathway activation in response to TNF or IL-1β as well as partial impairment of the response to toll-like receptor (TLR) stimuli. The inflammatory phenotype was determined to originate from monocytes, with monocytes displaying hyper-responsiveness to IL-1β in terms of inflammatory cytokines produced compared with healthy control monocytes. The clinical and cellular phenotypes in the HOI1-deficient cases overlap with those seen in an individual with homozygous loss of function mutations in HOIP [77]. The publication of a series of ten cases from eight families with polyglucosan storage myopathy harbouring either homozygous or compound heterozygous mutations in HOI1 [78] suggests that mutations in this gene, and potentially other components of LUBAC, may also present with a more limited clinical phenotype, and that much remains to be learnt about genotype–phenotype correlations in these disorders.

Classifying these as autoinflammatory diseases inherently fails to acknowledge the associated immunodeficiency, and vice versa. A similar problem concerns the conditions caused by mutations in PLCγ2 encoding phospholipase c γ-2 (PLCy2), PLCγ2-associated antibody deficiency and immune dysregulation (PLAID) and autoinflammation and PLAID (APLAID) [79,80]. PLCγ2 was linked to autoimmune and autoinflammatory diseases initially through an N-ethyl-N-nitrosourea (ENU) mutagenesis screen [81]. A heterozygous point mutation in PLCγ2 in mice led to spontaneous inflammation, arthritis and dermatitis with evidence of immune complex driven glomerulonephritis. Subsequently, by sequencing three families with dominantly inherited cold-induced urticaria, antibody deficiency and autoimmunity, in-frame deletions in PLCγ2 were identified and shown to segregate with disease [79]. These deletions affected the autoinhibitory C-terminal Src-homology 2 domain and resulted in constitutive phospholipase activity. Interestingly, and somewhat contradictory to the increased activity of PLCγ2, B cells and natural killer (NK) cells demonstrated reduced calcium flux and reduced phosphorylation of mitogen-activated protein kinase (MAPK) in response to stimulation with either IgM cross-linking or cross-linking of activating receptors respectively. This was determined to be temperature specific, however, with increasing MAPK pathway phosphorylation and cytosolic calcium in response to decreasing temperatures. This description was quickly followed by one of a family with a dominantly inherited autoinflammatory condition who had a missense mutation in PLCγ2. Unlike the previous
report, the individuals had no evidence of autoimmunity, but did have hypogammaglobulinaemia and markedly reduced class switched memory B cells in addition to inflammatory manifestations in the form of skin inflammation and granulomata, enterocolitis, bronchiolitis and uveitis [80]. Of the two cases described, neither had cold-induced symptoms. Increased baseline PLCγ2 activity was noted in an overexpression COS-7 cell model. Chae et al. [82] progressed the understanding of the inflammatory manifestations of APLAID by showing that the increased activity of PLCγ2 and subsequent increase in inositol and release of Ca2+ from ER stores, previously established by Kuroskai and Tsukada [83], resulted in increased NLRP3 activation and IL-1β release when assessing PBMCs from cases compared with healthy controls. It would be interesting to determine whether the same increase in NLRP3-driven IL-1β is seen when PBMCs from PLAIID subjects are examined, as their inflammatory phenotype was not as profound, and was temperature dependent. Furthermore, the partial response to IL-1β-targeted therapy [80] suggests that there may be more than NLRP3 driving the inflammatory disease.

Clearly, more information is needed to tease out the different immunological consequences of mutations in PLCG2. This is, of course, not unique to this autoinflammatory disease. With the description of rare disorders and involvement of novel genes and mutations, one can expect the phenotypic spectrum to evolve as more cases are reported. In the case of deficiency of adenosine deaminase 2 (DADA2), homozygous loss of function mutations in CECR1 were found in individuals with polyarteritis nodosa [84] as well as early onset stroke, vasculopathy and febrile episodes [85]. Although immunodeficiency and autoimmunity were not a major feature, IgM deficiency was noted in a number of cases [85]. Treatment of ten individuals with TNF targeting therapy by Levy-Lahad et al. led to significant clinical improvement, highlighting the role of this cytokine in disease pathogenesis [84]. The response to TNF directed therapy has since been reproduced [86,87]. In a subsequent study of 48 cases with polyarteritis nodosa associated with livedo reticularis and/or strokes,Gattorno et al. performed Sanger sequencing of CECR1 and determined that 15 cases harboured homozygous or compound heterozygous mutations [88]. Since the time of the original description, there has been an expansion of the clinical phenotype of cases with DADA2, from cytopenias and pure red cell aplasia [89], to lymphoproliferative disease [90-92], and combined immune deficiency, as well as common variable immune deficiency (CVID) [93]. Indeed, a cohort study of 181 cases with antibody deficiency diagnosed 11 individuals with mutation and enzyme deficiency confirmed DADA2 [94]. An interesting finding in this group was that anti-TNF therapy resulted in an improvement in IgM levels in one case, and there was an inverse correlation between c-reactive protein (CRP) and IgG in another. Further complicating the potential mechanisms of this disease, individuals with DADA2 have also been reported to have an IFN gene signature [95,96]. Researchers investigated individuals with features overlapping with AGS-5 (caused by mutations in SAMHD1). In each report, cases had enhanced IFN stimulated gene expression. These cases were treated with a range of immunosuppressive agents but had not been trialled on anti-TNF therapy. Given the reports of profound response in individuals with DADA2 to this therapy, it would be interesting to determine whether the IFN gene signature is abrogated with the use of anti-TNF therapy.

Furthermore, a number of conditions classified as disorders of predominantly antibody deficiency by the IUIS have marked autoinflammatory features. The syndrome of sierodoblastic anemia with B-cell immunodeficiency, periodic fevers and developmental delay (SIFD) was first described by Wiseman et al. in 2013 [97], with 11 out of the 12 cases described experiencing periodic fevers. It was subsequently determined to be caused by homozygous or compound heterozygous mutations in TRNT1 [98], encoding the CCA-adding enzyme tRNA nucleotidyltransferase [99]. Aksen-tijevich et al. investigated the inflammatory phenotype of these cases, noting markedly elevated acute phase reactants and inflammatory cytokines in cases with active disease [100]. The authors documented reduced expression of mature cytosolic tRNA, as well as increased reactive oxygen species when corrected for live cells in fibroblasts after 72 h compared with healthy controls. Using an siRNA knockdown THP-1 cell model, TRNT1-knockdown cells demonstrated increased IL-1β production at baseline and in response to LPS which was reversed with the small molecule NLRP3 inhibitor MCC950, suggesting an NLRP3-dependent inflammatory phenotype.

Autoinflammatory disease classification summary
From the above discussion, it is apparent that there are significant barriers to a simple definition or classification criteria for what are considered monogenic autoinflammatory disorders. As research progresses, the inflammatory component of disorders previously considered to be primarily of immune deficiency or autoimmunity will become more apparent. Provided in Figure 2 is a summary of conditions listed as autoinflammatory disorders in the latest IUIS Expert Committee for Primary Immunodeficiency (2017) as well as the Infevers database, documenting the spectrum of immunological manifestations recognised to date.
<table>
<thead>
<tr>
<th>Cytokine System</th>
<th>Condition</th>
<th>Gene/s</th>
<th>Protein</th>
<th>MOI</th>
<th>GO/FLOF</th>
<th>Pathway</th>
<th>System Involved</th>
<th>Human cell model</th>
<th>Potential murine model</th>
<th>Reference/s</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADAM17</td>
<td>ADAM17</td>
<td>ADAM17</td>
<td>AR</td>
<td>LOF</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Skin GIT</td>
<td>PBMG: ↓ TNF-α response to LPS, PMA + anti-CD3/anti-CD28 antibodies</td>
<td>Nil</td>
<td></td>
</tr>
<tr>
<td>AGB1</td>
<td>TNEX1</td>
<td>TRENX1</td>
<td>α or AD</td>
<td>LOF</td>
<td>FN</td>
<td>T1RN</td>
<td>CNS</td>
<td>Human neural stem cell-derived astrocytes, primary astrocytes, brain-derived endothelial cells; shRNA knockdown → IRN gene signature + proinflammatory cytokines</td>
<td>Trex1−/− mice</td>
<td></td>
</tr>
<tr>
<td>AGB2</td>
<td>RINASEH2B</td>
<td>RINASEH2B</td>
<td>AR</td>
<td>LOF</td>
<td>FN</td>
<td>T1RN</td>
<td>CNS</td>
<td>Human neural stem cell-derived astrocytes, primary astrocytes, brain-derived endothelial cells; shRNA knockdown minimal change in ISGF3/Galectin profile</td>
<td>RSPr2−/− mice</td>
<td></td>
</tr>
<tr>
<td>AGB3</td>
<td>RINASEH2C</td>
<td>RINASEH2C</td>
<td>AR</td>
<td>LOF</td>
<td>FN</td>
<td>T1RN</td>
<td>CNS</td>
<td>Human neural stem cell-derived astrocytes, primary astrocytes, brain-derived endothelial cells; shRNA knockdown minimal change in ISGF3/Galectin profile</td>
<td>Samhd1−/− mice</td>
<td></td>
</tr>
<tr>
<td>AGB4</td>
<td>SAMHD1</td>
<td>SAMHD1</td>
<td>LOF</td>
<td>FN</td>
<td>T1RN</td>
<td>CNS</td>
<td>Human neural stem cell-derived astrocytes, primary astrocytes, brain-derived endothelial cells; shRNA knockdown minimal change in ISGF3/Galectin profile</td>
<td>Samhd1−/− mice</td>
<td></td>
<td>[67,149,155-157]</td>
</tr>
<tr>
<td>AGB5</td>
<td>ADARD1</td>
<td>ADARD1</td>
<td>AR</td>
<td>LOF</td>
<td>FN</td>
<td>T1RN</td>
<td>CNS</td>
<td>HEK293T cells: IFN reporter assay</td>
<td>Actg1−/− Scl-Cre ERT2+ mice</td>
<td></td>
</tr>
<tr>
<td>AGB7</td>
<td>RNASEH2A</td>
<td>RNASEH2A</td>
<td>AR or LOF</td>
<td>FN</td>
<td>T1RN</td>
<td>CNS</td>
<td>Multiple</td>
<td>Multiple</td>
<td>Multiple*</td>
<td>[149-161]</td>
</tr>
<tr>
<td>AAC1</td>
<td>NLRP3</td>
<td>NLRP3</td>
<td>AD</td>
<td>GOF</td>
<td>Inflam</td>
<td>IL-1β</td>
<td>Multiple</td>
<td>Monocytes:↑ IL-1β in response to Pgl</td>
<td>mu-NLRP3 transgenic mice</td>
<td>[147,32,163-165]</td>
</tr>
<tr>
<td>AIEC</td>
<td>NLRP3</td>
<td>NLRP3</td>
<td>AD</td>
<td>GOF</td>
<td>Inflam</td>
<td>IL-1β</td>
<td>Multiple</td>
<td>Monocytes:↑ IL-1β in response to Pgl</td>
<td>mu-NLRP3 transgenic mice</td>
<td>[147,32,163-165]</td>
</tr>
<tr>
<td>AIJUK</td>
<td>COPA</td>
<td>COPA</td>
<td>AD</td>
<td>Dominant negative</td>
<td>NF-eB</td>
<td>TNF-α</td>
<td>Multiple</td>
<td>Multiple</td>
<td>Multiple*</td>
<td>[149,150]</td>
</tr>
<tr>
<td>APLA</td>
<td>PLCG2</td>
<td>PLCγ2</td>
<td>AD</td>
<td>GOF</td>
<td>Inflam</td>
<td>IL-1β</td>
<td>Multiple</td>
<td>Multiple</td>
<td>Multiple*</td>
<td>[149,150]</td>
</tr>
<tr>
<td>Blau syndrome</td>
<td>NOD2</td>
<td>NOD2</td>
<td>AD</td>
<td>GOF</td>
<td>NF-eB</td>
<td>Multiple</td>
<td>T NF-α</td>
<td>Multiple</td>
<td>Multiple*</td>
<td>[149,150]</td>
</tr>
<tr>
<td>CAPS</td>
<td>NLRP3</td>
<td>NLRP3</td>
<td>AD</td>
<td>GOF</td>
<td>Inflam</td>
<td>IL-1β</td>
<td>Multiple</td>
<td>Multiple</td>
<td>Multiple*</td>
<td>[149,150]</td>
</tr>
<tr>
<td>Cherubism</td>
<td>SH3BP2</td>
<td>SH3BP2</td>
<td>AD</td>
<td>GOF</td>
<td>NF-eB</td>
<td>Multiple</td>
<td>TFα</td>
<td>Multiple</td>
<td>Multiple*</td>
<td>[149,150]</td>
</tr>
<tr>
<td>CDDA2</td>
<td>CEG1</td>
<td>CEG1</td>
<td>AD</td>
<td>LOF</td>
<td>Unknown</td>
<td>NF-eB</td>
<td>Multiple</td>
<td>Multiple</td>
<td>Multiple*</td>
<td>[149,150]</td>
</tr>
<tr>
<td>DIRA</td>
<td>IL-1RN</td>
<td>IL-1Ra</td>
<td>AR</td>
<td>LOF</td>
<td>Multiple</td>
<td>Multiple</td>
<td>Multiple</td>
<td>Multiple</td>
<td>Multiple*</td>
<td>[149,150]</td>
</tr>
<tr>
<td>DIRA</td>
<td>IL-1RN</td>
<td>IL-1Ra</td>
<td>AR</td>
<td>LOF</td>
<td>Multiple</td>
<td>Multiple</td>
<td>Multiple</td>
<td>Multiple</td>
<td>Multiple*</td>
<td>[149,150]</td>
</tr>
<tr>
<td>DIRA</td>
<td>IL-1RN</td>
<td>IL-1Ra</td>
<td>AR</td>
<td>LOF</td>
<td>Multiple</td>
<td>Multiple</td>
<td>Multiple</td>
<td>Multiple</td>
<td>Multiple*</td>
<td>[149,150]</td>
</tr>
<tr>
<td>DIRA</td>
<td>IL-1RN</td>
<td>IL-1Ra</td>
<td>AR</td>
<td>LOF</td>
<td>Multiple</td>
<td>Multiple</td>
<td>Multiple</td>
<td>Multiple</td>
<td>Multiple*</td>
<td>[149,150]</td>
</tr>
</tbody>
</table>
Table 1 Monogenic autoinflammatory disorder summary table (Continued)

<table>
<thead>
<tr>
<th>Condition</th>
<th>Gene/s</th>
<th>Protein</th>
<th>MOI</th>
<th>GOF/LOF</th>
<th>Pathway</th>
<th>Cytokine group</th>
<th>System involved</th>
<th>Human cell model</th>
<th>Potential murine model</th>
<th>Reference/s</th>
</tr>
</thead>
<tbody>
<tr>
<td>EOBD</td>
<td>ITGAM ITGAV</td>
<td>α/β integrins</td>
<td>AR</td>
<td>LOF</td>
<td>Other</td>
<td>IL-10</td>
<td>GFT</td>
<td>PMBC: Failure of IL-10 to c LP-induced TNF α in patients with receptor mutations; More rapid TNF α to response to LPS. Failure to phosphorylate STAT3 in response to IL-10</td>
<td>SCID/human IL-10−/− Cre or IL-10R−/− mice</td>
<td>[47,48,116]</td>
</tr>
<tr>
<td>FOAS2</td>
<td>NLRP12 NLRP12</td>
<td>NLRP12</td>
<td>AD</td>
<td>LOF</td>
<td>NF-κB</td>
<td>TNF-α</td>
<td>Skin</td>
<td>Multiple</td>
<td>HEK293T cells: NF-κB luciferase assay</td>
<td>NLRP12−/− mice</td>
</tr>
<tr>
<td>FMF</td>
<td>MEFV</td>
<td>Pyrin</td>
<td>AR = AD</td>
<td>GOF</td>
<td>Inflamm</td>
<td>IL-1β</td>
<td>Multiple</td>
<td>PMBC: no IL-18 secretion when cultured. TNF α in response to LPS (inconsistent). Anti-CD14/CD20 stimulation → IL-17 and IL-22</td>
<td>Neutrophils: possible release of IL-18 through NETS</td>
<td>[176, 179, 187, 188]</td>
</tr>
<tr>
<td>H syndrome</td>
<td>SLC29A3 SLC29A3</td>
<td>SLC29A3</td>
<td>AR</td>
<td>LOF</td>
<td>NF-κB</td>
<td>Inflamm</td>
<td>Unknown</td>
<td>Multiple</td>
<td>HEK293T cells: NF-κB luciferase assay</td>
<td>EVG−/− mice</td>
</tr>
<tr>
<td>HAO2</td>
<td>TNFAIP3</td>
<td>A20</td>
<td>AR</td>
<td>LOF</td>
<td>NF-κB</td>
<td>Inflamm</td>
<td>IL-10</td>
<td>Multiple</td>
<td>PMBC, fibroblasts: nuclear translocation p65 at rest + with TNF stimulation</td>
<td>Mv−/− mice</td>
</tr>
<tr>
<td>HID1</td>
<td>MK</td>
<td>MK</td>
<td>AR</td>
<td>LOF</td>
<td>NF-κB</td>
<td>Inflamm</td>
<td>IL-1β</td>
<td>Multiple</td>
<td>PMBC: 1 IL-1β, 6- and TNF-α at rest with stimulation</td>
<td>B4VCL. accumulation unphosphorylated Tab proteins (temperature dependent)</td>
</tr>
<tr>
<td>HOIL1 deficiency</td>
<td>RBCK1 HOIL1</td>
<td>Hoil1</td>
<td>AR</td>
<td>LOF</td>
<td>NF-κB</td>
<td>Multiple</td>
<td>Multiple</td>
<td>Fibroblasts, B cells:</td>
<td>Rap−/− mice (ovary)</td>
<td>[77]</td>
</tr>
<tr>
<td>HYDM1</td>
<td>NLRP7 NLRP7</td>
<td>NLRP7</td>
<td>AR</td>
<td>LOF</td>
<td>NF-κB</td>
<td>Multiple</td>
<td>Multiple</td>
<td>Fibroblasts, B cells: JNK phosphorylation, IL-1β production in response to TNF or IL-1β stimulation</td>
<td>HIP−/− mice (embryonically lethal), Various crosses</td>
<td>[118, 181, 196-199]</td>
</tr>
<tr>
<td>Majeed syndrome</td>
<td>LPA2</td>
<td>Lpin 2</td>
<td>AR</td>
<td>LOF</td>
<td>Inflamm</td>
<td>IL-1β</td>
<td>Bone</td>
<td>Skin</td>
<td>Multiple</td>
<td>HEK293T cells: ASC speck assay, restoration of inflammasome activity</td>
</tr>
<tr>
<td>MSPC</td>
<td>NLRP1</td>
<td>NLRP1</td>
<td>AD</td>
<td>GOF</td>
<td>Inflamm</td>
<td>IL-1β</td>
<td>Skin</td>
<td>Multiple</td>
<td>HEK293T cells: ASC speck assay, reconstitution of inflammasome 1p6 IL-1β cleavage</td>
<td>NLRP1−/−/− mice</td>
</tr>
<tr>
<td>CRAS</td>
<td>OTULIN</td>
<td>Otulain</td>
<td>AR</td>
<td>LOF</td>
<td>NF-κB</td>
<td>TNF</td>
<td>Multiple</td>
<td>PMBC: spontaneous IL-18 secretion c/w healthy control</td>
<td>CreERT2-Obapt/+ mice</td>
<td>[205,206]</td>
</tr>
<tr>
<td>PAAN</td>
<td>MEFV</td>
<td>Pyrin</td>
<td>AD</td>
<td>GOF</td>
<td>Inflamm</td>
<td>?Multiple</td>
<td>Skin</td>
<td>Multiple</td>
<td>Monocyte: ASC speck formation, caspase-1 activity, c/w healthy control</td>
<td>Nil</td>
</tr>
<tr>
<td>PAAPA</td>
<td>PSTPIP1 PSTPIP1</td>
<td>PSTPIP1</td>
<td>AD</td>
<td>Unknown</td>
<td>Inflamm</td>
<td>IL-1β</td>
<td>Skin, Joints</td>
<td>Multiple</td>
<td>HEK293T cells: Transient cotransfection, Mutant PSTPIP1 hyperphosphorylated and binding to pyrin</td>
<td>Rosa−/− mice</td>
</tr>
</tbody>
</table>

Continued over
## Table 1 Monogenic autoinflammatory disorder summary table (Continued)

<table>
<thead>
<tr>
<th>Condition</th>
<th>Genes/s</th>
<th>Protein</th>
<th>MOI</th>
<th>GOF/LOF</th>
<th>Pathway</th>
<th>Cytokine group</th>
<th>System involved</th>
<th>Human cell model</th>
<th>Potential murine model</th>
<th>Reference/s</th>
</tr>
</thead>
<tbody>
<tr>
<td>PLAID</td>
<td>PLCG2, PLCY2</td>
<td>AD</td>
<td>GOF</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Multiple</td>
<td>COST, A20 cells: transfection model; Mutants ↑ phospholipase activity at subphysiological temperatures</td>
<td>Lmp7+/− mice</td>
<td>Multiple</td>
<td>[79]</td>
</tr>
<tr>
<td>PRAAS</td>
<td>PSMB8, PSMD8, PSMB9, PSMB4, PSMA3, PSMB4, PSMA3, PSMB4, PSMA3, POCP</td>
<td>AR</td>
<td>LOF</td>
<td>TNF-α, IFN</td>
<td>T1IFN</td>
<td>Multiple</td>
<td>HeLa cells: Transfection studies show poor formation of proteasome with mutant cDNA WT</td>
<td>Lmp7+/− mice</td>
<td>Multiple</td>
<td>[59,214]</td>
</tr>
<tr>
<td>PRR</td>
<td>CARD14</td>
<td>AD</td>
<td>GOF</td>
<td>NF-κB</td>
<td>Skin</td>
<td>Multiple</td>
<td>Primary keratinocytes: Ubiqutin aggregation</td>
<td>Nil</td>
<td>Nil</td>
<td>[215,216]</td>
</tr>
<tr>
<td>Putative</td>
<td>AP153</td>
<td>AR</td>
<td>LOF</td>
<td>TNF-α, IL-1</td>
<td>Sting</td>
<td>Skin</td>
<td>Primary keratinocytes and dermal fibroblasts: abnormal autophagosome, accumulation of p62. Abnormal TLR2/6 signaling</td>
<td>Nil</td>
<td>Nil</td>
<td>[217,218]</td>
</tr>
<tr>
<td>SAWI</td>
<td>TMEM173</td>
<td>AD</td>
<td>GDF</td>
<td>IFN</td>
<td>T1IFN</td>
<td>Multiple</td>
<td>HEK290T cells: IFN-α reporter assay, Immunoblot analysis of Sting pathway</td>
<td>Sto6+/− mice</td>
<td>Multiple</td>
<td>[16-18]</td>
</tr>
<tr>
<td>SPENCD</td>
<td>ACP5, ACP5</td>
<td>AR</td>
<td>LOF</td>
<td>IFN</td>
<td>T1IFN</td>
<td>Multiple</td>
<td>Primary human macrophages: colocalisation studies; Plasmacytid dendritic cells: co-localisation studies; IL-10 stimulation in shRNA-ACP5 knockout studies → ↑ transcription ISGs</td>
<td>Acp5+/− mice</td>
<td>Multiple</td>
<td>[219-222]</td>
</tr>
<tr>
<td>TRAPS</td>
<td>TNFR5A1</td>
<td>AD</td>
<td>Unknown</td>
<td>NF-κB, IL-1β</td>
<td>Multiple</td>
<td>Multiple</td>
<td>PBMNC: ↑ surface expression TNFR1 + ↓ shedding (conflicting data)</td>
<td>Trktra75/5+ mice</td>
<td>Multiple</td>
<td>[1,9-11,13,223-232]</td>
</tr>
<tr>
<td></td>
<td>TNFR1</td>
<td>AD</td>
<td>GDF</td>
<td>IFN</td>
<td>T1IFN</td>
<td>Multiple</td>
<td>Primary human macrophages: colocalisation studies; Plasmacytid dendritic cells: co-localisation studies; IL-10 stimulation in shRNA-ACP5 knockout studies → ↑ transcription ISGs</td>
<td>Usp18−/− mice</td>
<td>Multiple</td>
<td>[233]</td>
</tr>
<tr>
<td>USP18 defect</td>
<td>USP18, USP18</td>
<td>AR</td>
<td>LOF</td>
<td>IFN</td>
<td>T1IFN</td>
<td>Multiple</td>
<td>Primary dermal fibroblasts: ↑ transcription ISG after IFN stimulation</td>
<td>Nil</td>
<td>Nil</td>
<td>[234]</td>
</tr>
<tr>
<td>XLPDR</td>
<td>POLA1, POLA1</td>
<td>XR</td>
<td>LOF</td>
<td>NF-κB</td>
<td>T1IFN</td>
<td>Multiple</td>
<td>Primary dermal fibroblasts: ↑ TNF + NF-κB response to stimulation with poly(dA:dT) or TNF; TNF and NF-κB pathway activation; ↑ RNA/DNA levels; Lentiviral transduction of WT rescued phenotype</td>
<td>Nil</td>
<td>Nil</td>
<td>[234]</td>
</tr>
</tbody>
</table>

Abbreviations: AD, autosomal dominant; AIADK, autoinflammation with arthritis and dyskeratosis; AID, autoinflammatory disorder; AIFEC, autoinflammation with infantile enterocolitis; AIILJK, autoimmune interstitial lung, joint and kidney disease; AR, autosomal recessive; BLCL, EBV-transformed B-lymphoblastoid cell lines; c/w, compared with; CD, cluster of differentiation; COPA, coatomer subunit α; DIRA, deficiency of IL-1 receptor antagonist; ER, endoplasmic reticulum; FCAS2, familial cold autoinflammatory syndrome 2; GIT, gastrointestinal tract; GOF, gain of function; HIDS, hyper IgD syndrome, HYDM1, hydatidiform molar pregnancy; Infiam, inflammation; ISG, IFN-stimulated gene; LOF, loss of function; MOI, mode of inheritance; MSCP, multiple self-healing palmoplantar carcinoma; NAFTac1, nuclear factor of activated T cell, cytoplasmic 1; CRAS, cutaneous-related autoinflammatory syndrome; PAANOD, pyrin-associated autoinflammation with neutrophilic dermatosis; POLA, DNA polymerase α catalytic subunit; PRP, pityriasis rubra pilaris; SMS, Singleton–Merten syndrome; SPENDC, spondyloenchondrodysplasia; T1IFN, type 1 IFN; XLPDR, x-linked pigmentary disorder, reticulate, with systemic manifestations. *Murine model prior to the description of monogenic condition.
Genetic sequencing of autoinflammatory disorders

The phenotypic heterogeneity of what is considered a monogenic autoinflammatory disorder, as well as the explosion in the number of newly described conditions, coincides with advances in genetic sequencing techniques. The gene mutated in FMF was determined to be MEFV using positional cloning methods in 1997, and since this time many more disease-causing genes have been recognised (Figure 3). Next-generation sequencing (NGS) technology has been used in the description of these conditions since 2012, starting with the identification of RBCK1 as the gene implicated in HOIL1 deficiency [76].

NGS

The now widely adopted NGS, also known as massive parallel or deep sequencing, is a broad term encompassing a number of different technologies that share the ability to generate and analyse millions of sequences per run. There are a large number of platforms on which NGS can be performed, and the specifics of the sequencing method varies depending on the instrument used [102]. In general, the sequencing process involves the preparation of a library of short DNA fragments through either enzymatic or sonication techniques. These short strands of DNA are then ligated to generic adapters in vitro. PCR amplification follows, performed using either emulsion PCR in oil–water emulsion micelles, or bridge PCR on a solid surface coated with complementary primers. Subsequent sequencing of the amplicon is performed by either pyrosequencing, sequencing by ligation or sequencing by synthesis. The large number of short reads generated from this process must then be aligned against a reference sequence. A plethora of software have been developed not only to align the reads, but to also determine where deviations from a reference sequence exist. Furthermore, considering that WES or WGS of an individual identifies 20000 or 4000000 variants...
respectively, an appropriate filtering strategy must be employed to determine which of these variants are potentially pathogenic [103,104].

NGS has been employed in the diagnostic evaluation of individuals with autoinflammatory disorders. Ceccherini et al. compared the performance of three NGS platforms in a pilot study interrogating 10 genes (MEFV, MVK, TNFRSF1A, NLRP3, NLRP12, NOD2, PSTPIP1, ILIRN, LPIN2 and PSMB8) from 50 cases with genetically confirmed autoinflammatory disorders [105]. The expected mutations were correctly called in most cases, although there was a failure to detect p.Val377Ile MVK in a number of cases due to low coverage. Additional variants were also noted, a number of which were false positives and detected on only one of the three platforms used. Importantly, true positive incidental variants did not alter the clinical diagnosis or management of the individual. Taking a different approach, Nakayama et al. [106] prospectively recruited individuals with a clinical diagnosis of an autoinflammatory disorder prior to any genetic testing. Using an MiSeq platform developed in house, they sequenced 9 genes (ILIRN, MEFV, MVK, NLRP12, NLRP3, NOD2, PSMB8, PSTPIP1 and TNFRSF1A) in 108 cases. A total of 27 missense mutations were identified and confirmed with Sanger sequencing. Unfortunately, the authors did not outline any genotype–phenotype correlation, nor did they include positive controls to ensure that all pathogenic mutations were detected. A further addition to the literature was by Omoyinmi et al. [107] with their development of a vasculitis and inflammation panel targeting up to 166 genes. Initially, 16 samples with known pathogenic mutations were analysed and the best performing pipeline carried over to the assessment of individuals with unknown diagnosis. Pathogenic mutations were detected in 12% of cases, and likely pathogenic variants in 22%. Furthermore, the depth of coverage was sufficient to be able to detect a 3% somatic mosaicism in NLRP3.

**Somatic mosaicism**

Somatic mosaicism in NLRP3 causing disease was first described in 2005 in an individual with a p.Tyr507Cys variant occurring at a frequency of 16.7% detected using Sanger sequencing [108]. Somatic mosaicism in NLRP3 has since been reported by multiple groups with a mutation frequency as low as 2.7% noted [109-116]. Importantly, a recent study highlighted that NGS was able to detect somatic NLRP3 mutations in eight individuals symptomatic of CAPS who had previously tested negative for mutations in NLRP3 sequencing using Sanger techniques [116]. Retrospective review of the Sanger chromatogram identified small peaks in only three of the eight cases, each with an allele frequency
of greater than 10%, suggesting that Sanger sequencing is not a sensitive technique for detecting low frequency somatic mosaicism.

**Autoinflammatory genetics summary**

While the use of NGS panels for the diagnosis of autoinflammatory disorders in the clinical setting is increasing, the key limitation from a research perspective is the inability to discover new disease-causing genes. In using WES or WGS, novel variants in genes known to cause disease, and also variants in novel genes, may be uncovered. The rationale for the use of WES is based on the finding that the majority of pathogenic variants causing Mendelian diseases that have been identified to date are located in protein-coding regions [117–119]. While WGS has the benefit of capturing introns and intergenic regions, and detecting copy number variants [104], a large volume of data must be interrogated, and the bioinformatics analysis is complex. Both strategies raise the possibility of detecting an incidental finding that has implications for the health of the individual and their family. Furthermore, neither method negates the requirement for the validation of pathogenicity of a novel variant.

**Modelling monogenic autoinflammatory disorders**

Modelling genetic findings experimentally is of great importance in determining the clinical significance of a novel variant. In recent years, many groups have taken advantage of clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing techniques. CRISPR/Cas9 gene editing utilises features of an adaptive immune response seen in bacteria and archaea.

**CRISPR approaches for functional validation**

CRISPR/Cas9 techniques have improved the ability to create models of diseases caused by point mutations. Previously, creating point mutations in mice would require homologous recombination in embryonic stem cells, a lengthy and expensive process to generate a homozygous mouse strain [120]. In *vivo* editing with CRISPR/Cas9 has allowed for genome editing of fertilised mouse eggs [121,122]. Briefly, plasmids with DNA encoding the editing tools, including the guide RNA and Cas9, are injected into the cytoplasm of a one-cell embryo, generating a target-specific double-strand break (DSB). The subsequent repair of this break is mediated by non-homologous end joining (NHEJ) or homology directed repair (HDR). The former often results in frameshift mutations and loss of function. HDR, on the other hand, can result in substitutions, insertions or deletions if the one-cell embryo is co-injected with a single-strand oligonucleotide (ssOligo) that acts as a template. Soon after this technique was first published, the efficiency of gene disruption by frameshift mutations through NHEJ using this method was reported to be approximately 80–90% whereas introducing a point mutation through HDR is approximately 50–80% [122,123].

Introduction of point mutations in human cells using CRISPR/Cas9 techniques has also been described. Early reports of CRISPR/Cas9 editing in HEK293T cells demonstrated NHEJ efficiency of up to 33% [124–127], but HDR efficiency of only 3–8% [126]. Improved efficacy was noted through cell synchronisation techniques that control the timing of delivery of single guide RNA (sgRNA) and ssOligo to HEK293T cells, with HDR in up to 38% of cells [128]. Various strategies have also been employed in an attempt to improve efficiency in cells that are difficult to nucleofect, a process by which components of the editing system are delivered to the nucleus of the target cell, including the use of a ssDNA template provided by recombinant adeno-associated virus (rAAV) [129,130]. The process, however, remains less efficient than NHEJ and its widespread application in research is still limited.

A significant recent addition to the literature has been the description ‘base editors’, able to create point mutations in human cell lines without generating a DSB. In the initial descriptions, a catalytically dead Cas9 was fused to a cytidine deaminase enzyme, with the unit guided to a locus of interest with an sgRNA [131,132]. This complex allowed for a targeted C·G to T·A substitution in human and murine cell lines in up to 40% of total sequencing reads, with a maximum base editing yield possible of 50%. Subsequent base editors have included the adaptation of tRNA adenosine deaminase to edit DNA, allowing for A·T to G·C conversion [133]. The significance of this development in the potential for disease modelling and future gene editing was highlighted by the correction of the *c.845G>A HFE* mutation implicated in hereditary haemochromatosis in an immortalised-lymphoblastoid cell line [133]. Despite the difficulty with which these cells are transfected, an efficiency rate of 28% was noted, with no off-target effects. Similar to the process of CRISPR/Cas9 with HDR, this technique is not yet used widely. However, significant advances in a short period of time suggests that either may become a routine method for modelling diseases caused by point mutations.
Autoinflammatory disease models using mice

*In vivo* murine models have provided great insight into disease pathology given genetic homologies between humans and mice and the ability to create transgenic, knockout and knockin mice. For example, the initial murine model of CAPS published in 2009 by Hoffman et al. recapitulated the IL-1β-mediated inflammation [134]. Furthermore, a number of teams have used murine models to explore the skeletal consequences of CAPS [135,136]. More recently, the generation of Nlrp3 mutant mice on Il1b/Il18, casp-1/casp-11 or Tnf-deficient backgrounds raised the possible role of TNF in CAPS disease pathology [137]. There are, however, shortcomings here. The recent attempt to model LPS-responsive and beige-like anchor protein (LRBA) deficiency using Lrba−/− mice, in which humans cause a range of manifestations including autoimmunity, hypogammaglobulinaemia, organomegaly and chronic diarrhoea [138], failed to recapitulate the clinical or immunological phenotype [139,140]. Furthermore, differences between murine and human pyrin led to many years of work predicated on pyrin as anti-inflammatory, rather than an inflammasome forming protein. Modelling of disorders that act through the pyrin pathway, such as Pyogenic Arthritis, Pyoderma gangrenosum and Acne (PAPA) syndrome caused by mutations in PSTPIP1 may thus be similarly problematic. Additionally, humanised mouse models, using immunodeficient mice engrafted with human haematopoietic cells, are useful in the study of haematopoiesis, but have been limited in the investigation of the innate immune system due to quantitative and functional deficiencies of a number of cells including monocytes and macrophages [141].

Autoinflammatory subject derived induced pluripotent stem cells

An alternative method of modelling autoinflammatory disorders is the use of subject-derived induced pluripotent stem cells (iPSCs). This method of reprogramming somatic cells to pluripotency [142] allows for indefinite propagation as well as differentiation to a variety of human cell types that would previously have been unobtainable [143-145]. Saito et al. utilised this method in the investigation of autoinflammatory disorders involving NLRP3 [146] and NLRC4 [147]. Two individuals with somatic mutations in NLRP3 had both wild-type (WT) and mutant NLRP3 iPSC lines generated [146]. The WT iPSC lines served as a comparator, with the authors able to determine that only macrophages differentiated from mutant NLRP3 iPSC lines showed abnormal IL-1β secretion. A subsequent publication generated iPSC lines from an individual suspected of CAPS but without pathogenic mutations in NLRP3 [147]. Heterogeneous responses to LPS stimulation in the iPSC clones prompted WES, with clones having a robust response to LPS possessing a mutation in NLRC4. Subsequent deletion of NLRC4 using CRISPR/Cas9 techniques in the mutant clones abrogated the enhanced response to stimulation, indicating that the mutation was likely pathogenic. As the frequency of the mutation was later determined to be approximately 63%, WES would most likely have identified this as a candidate variant of interest. Furthermore, despite its promise, the generation of a cell line from case samples demands expertise, as well as specific ethical considerations. It also requires access to case samples which may be difficult in the case of critically ill individuals who succumb to disease prior to genetic evaluation.

Having said this, the use of these cells has the potential to overcome a significant limitation in the modelling of autoinflammatory disorders to date. Using either the genetic manipulation of healthy iPSCs or subject-derived iPSCs, it is possible to explore the effect of a genetic mutation on a variety of cell types. For example, in our recent paper exploring a novel NLRC4 variant, THP-1 monocyte like cells were used to model and the variant was determined to be pathogenic [31]. iPSCs would have permitted exploration of the effect of this variant on NK cells and T cells, allowing for addressing questions that remain unanswered including the pathogenesis of macrophage activation syndrome in this population. Likewise, the use of iPSCs differentiated to keratinocytes would allow interrogation of mechanisms of the dermatological manifestations in specific autoinflammatory disorders. As summarised in Table 1, most monogenic autoinflammatory disorders described to date have not had immunological assessment of multiple cell types.

Future directions and questions

Questions remain in the field about the phenotype–genotype correlation as well as phenotypic variability of individuals with a specific genetic variant. This includes disorders of ‘variable penetrance’. There are alternative explanations for differing phenotypes among cases with the same genetic variant. One consideration is the presence of another genetic variant that affects disease presentation. A true digenic disorder requires the inheritance of a distinct heterozygous mutation in two genes that, when inherited separately, do not cause a phenotype [235,236]. The broader term of epistasis refers to possible interactions between genes [237]. Determining genetic epistasis is complex and requires an appropriate pedigree, which includes more than one gene mutated in a single pedigree, a range of genetic permutations and at least one member with WT alleles in both genes [238,239].
Another possible explanation for the phenotypic heterogeneity among cases is epigenetic differences. Epigenetic processes such as DNA methylation, histone modifications, chromatin remodelling and non-coding RNAs can alter the activity of a gene without changing the DNA sequence. For example, a transcriptionally active gene has minimal DNA methylation and an open chromatic structure. Monozygotic and dizygotic twin studies of concordance have been used for some time to determine the contribution of a particular genotype to phenotype [240]. More recently, this has been combined with methods of quantifying epigenetic changes. In a study of monozygotic twins discordant for the clinical diagnosis of CVID, a DNA methylation array performed on CD19+ B cells revealed that both switched and unswitched memory B cells of the twin with CVID had higher DNA methylation in genes relevant to B-cell function [241]. This finding highlights that epigenetic factors could account for phenotypic variations. There have been two publications assessing DNA methylation in individuals with monogenic autoinflammatory disorders, but in each case the diseased population was compared with a healthy control [242,243]. Vento-Tormo et al. [243] assessed the DNA methylation status of genes encoding various components of the inflammasome in monocytes of cases with CAPS and compared this with healthy controls. They noted that genes such as IL1B, IL1RN and ASC were demethylated more efficiently in CAPS monocytes when compared with healthy controls, a feature that normalised when individuals were treated with anti-IL1 therapy. Determining the epigenetic factors contributing to the phenotypic variability of a particular genotype is not simple. With a small number of cases, one possible approach is to compare the methylation status of genes potentially involved in the phenotype observed. An alternative approach is genome-wide DNA methylation profiling [244]. However, drawing conclusions from only a few individuals with different genetic backgrounds may not be feasible.

Exploring factors that can account for this phenotypic variability may provide insight into the pathways involved in disease. Furthermore, the comprehensive genetic evaluation and investigation of various immune and non-immune cells of individuals with these conditions will likely enlighten the field to the intimate link between the innate and adaptive immune system as well as the role of ‘innate immune’ proteins in non-immune cells.

Funding
This work was supported by the Henry James Williams Scholarship (University of Melbourne) to F.M.; the Australian Genomics Health Alliance Ph.D. top-up award to F.M.; the NHMRC grants [grant numbers 1144282, 1142354, 1099262 (to S.L.M.); the Sylvia and Charles Viertel Foundation to S.L.M.; the HHMI-Wellcome International Research Scholarship to S.L.M.; and Glaxo-SmithKline to S.L.M.

Author contribution
This article has been adapted by F.M. and S.L.M. from the introductory chapter of F.M.’s doctoral thesis; ‘Novel genes and mechanisms in monogenic autoinflammatory disorders’ (2018, University of Melbourne).

Competing interests
The authors declare that there are no competing interests associated with the manuscript.

Abbreviations
AGS, Aicardi–Goutières syndrome; APLAID, autoinflammation and PLCγ2-associated antibody deficiency and immune dysregulation; CAPS, cryopyrin-associated periodic syndrome; CARD, caspase activation and recruitment domain; CRISPR, clustered regularly interspaced short palindromic repeat; CVID, common variable immune deficiency; DADA2, deficiency of adenosine deaminase 2; DITRA, deficiency in IL-36Ra; DSB, double-strand break; EBV, Epstein–Barr virus; FMF, familial Mediterranean fever; HDR, homology directed repair; HHT, Haematothrombocytopenia; HOIL1, haem-oxidised IRP2 ubiquitin ligase 1; HSC, haemopoietic stem cell transplantation; IFN, interferon; IL, interleukin; IL-36Ra, IL-36 receptor antagonist; IL1RaCp, IL-1 receptor accessory protein; IPS, induced pluripotent stem cell; JAK, Janus kinase; LPS, lipopolysaccharide; LUBAC, linear ubiquitin assembly complex; MAPK, mitogen-activated protein kinase; NF-κB, nuclear factor-κ-light-chain-enhancer of activated B cell; NGS, next-generation sequencing; NHEJ, non-homologous end joining; NHMRC, National Health and Medical Research Council; NK, natural killer; NLR, NOD-like receptor; NOD, nucleotide-binding oligomerization domain; PBMC, peripheral blood mononuclear cell; PRAAS, proteasome-associated autoinflammatory syndrome; rAAV, recombinant adeno-associated virus; rhIL-10, recombinant human IL-10; RNaseH2, ribonuclease H2; SAMHD1, SAM and HD domain containing protein 1; SAVI, STING-associated vasculopathy with onset in infancy; sgRNA, single guide RNA; ssOligo, single-strand oligonucleotide; STAT, signal transducer and activator of transcription; STING, stimulator of IFN gene; TAK1, transforming growth factor-β activated kinase-1; TNF, tumour necrosis factor; TNFR1, TNF receptor 1; TRAPS, TNF receptor associated periodic syndrome; WES, whole exome sequencing; WGS, whole genome sequencing; WT, wild-type.

Attribution License 4.0 (CC BY-NC-ND).
References


© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY-NC-ND).
48 Berg, D.J., Kuhn, R., Rajewsky, K., Muller, W., Menon, S., Davidson, N. et al. (1995) Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxin shock and the Shwartzman reaction but not endotoxin tolerance. J. Clin. Invest. 96, 2339–2347, https://doi.org/10.1172/JCI118290
Attribution License 4.0 (CC BY-NC-ND).
1918

© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY-NC-ND).
Clinical Science (2018) 132 1901–1924
https://doi.org/10.1042/CS20171498


